{"filing":{"accession_number":"0001193125-26-236862","cik":"0001783328","ticker":"TCRX","company_name":"TScan Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"d43301d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm"},"events":[{"id":10559,"run_id":9262,"accession_number":"0001193125-26-236862","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"TScan held its Annual Meeting on May 20, 2026, with shareholders voting on four proposals: election of Class II directors (Katina Dorton and R. Keith Woods), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval of an amendment to increase authorized common shares from 300 million to 600 million, and approval to adjourn the meeting. The increase in authorized shares is material to investors as it expands the company's capacity for equity issuance and signals potential future capital-raising or dilution.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6897,"accession_number":"0001193125-26-236862","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 600 million. While this is a structural corporate action that could signal future dilution or capital-raising plans, it is primarily a routine administrative amendment rather than a specific material event category. The increase in authorized shares is material to investors as it expands the company's capacity for equity issuance, but the taxonomy lacks a dedicated category for charter amendments; shareholder_vote_results would address the voting outcome separately (Item 5.07), making other_material the most appropriate classification for the amendment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:59.080196+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6898,"accession_number":"0001193125-26-236862","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from TScan's Annual Meeting held on May 20, 2026. The filing reports final voting tallies for four proposals: election of Class II directors (Katina Dorton and R. Keith Woods), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval of an amendment to increase authorized common shares from 300M to 600M, and approval to adjourn the meeting. The authorization increase is material to investors as it affects potential dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:59.080196+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6897,"accession_number":"0001193125-26-236862","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 600 million. While this is a structural corporate action that could signal future dilution or capital-raising plans, it is primarily a routine administrative amendment rather than a specific material event category. The increase in authorized shares is material to investors as it expands the company's capacity for equity issuance, but the taxonomy lacks a dedicated category for charter amendments; shareholder_vote_results would address the voting outcome separately (Item 5.07), making other_material the most appropriate classification for the amendment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:59.080196+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-05-22"},{"id":6898,"accession_number":"0001193125-26-236862","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from TScan's Annual Meeting held on May 20, 2026. The filing reports final voting tallies for four proposals: election of Class II directors (Katina Dorton and R. Keith Woods), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval of an amendment to increase authorized common shares from 300M to 600M, and approval to adjourn the meeting. The authorization increase is material to investors as it affects potential dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:59.080196+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-05-22"}]}